The unique and innovative iQ Group Global business model is transforming the biotech industry worldwide.
Our life science and pharmaceutical business unit collaborates with scientists the world over: Identifying and owning Intellectual Property (IP), creating and executing drug development plans from discovery to market. From simple chemical entities to complex genetic therapeutics and beyond, we are creating the medicines of the future.
Our dedicated investment banking business transforms biotech from an alternative investment option to a requisite mainstream capital market asset. We design and market innovative, structured financial products and solutions. These provide entry and exit, investment and divestment, in the 12 or more year drug development cycle. In this way the iQ Group Global is bridging strategic capital with innovative science.
The life science and pharmaceutical business provides scientific expertise in areas ranging from biotech IP asset management, medical/clinical research, regulatory and reimbursement strategy, medical affairs and pharmaceutical sales.
The investment banking business provides venture capital, structured financial products, funds management (iQ Series 8) and investment banking on a global scale.
Converging on the global investment and scientific community, The iQ Group Global plays a pivotal role in the evolution of the biotech sector. This positions The iQ Group as the ideal strategic partner for financial market participants, governments, research institutes and the broader biopharma community.
The iQ Group Global consists of the following six companies:
Bridging science with business
iQnovate is a scientifically driven life science asset management organisation. It has exceptional organic research and development capability. This enables iQnovate to conceptualise, source, validate and commercialise biotechnology assets that have extraordinary and potentially disruptive outcomes, thus advancing human health.
Translating science into capital and beyond
iQ3Corp is the world’s first dedicated life science corporate finance and advisory firm.
Eradicating disease through capital investment
iQX Investments is an investment company and fund manager specialising in the life science sector, supporting physicians, scientists and entrepreneurs who are building innovation based businesses.
Clinical Research Corporation (CRC)
Redefining Medical Affairs
CRC provides contract medical affairs services to the pharmaceutical industry throughout the drug lifecycle.
Shaping the future, together
FarmaForce is a contract sales organisation offering innovative sales solutions to the Australian pharmaceutical industry.
Investing in the medicines of the future
iQ Capital is the Group’s dedicated life science investment bank, physically creating the bridge between investors and the biopharma industry.